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ANESTHESIA AND ELECTROCONVULSIVE THERAPY 
SIVASANKARI RAJAMARTHANDAN 
ABSTRACT 
Background: Major Depressive Disorder (MDD) is a common mental health illness, 
characterized by persistent feelings of sadness, diminished interests, guilt, low-self 
esteem, and disturbances in sleep and appetite. A significant percentage of patients with 
MDD are treatment resistant. Electroconvulsive Therapy (ECT) is a biological procedure 
utilized for treatment resistant illnesses. Diagnosis and clinical conditions primarily 
dictate when ECT is the appropriate treatment modality for an individual. Circumstances 
requiring rapid clinical response, risks affiliated with alternative treatments, resistance to 
pharmacotherapy, and medical history are all factors that designate ECT as the treatment 
of choice.  
Methods: The objective of this systematic review was to examine how different 
anesthetics or combinations of agents affect ECT’s therapeutic efficacy in depressed, 
adult patients. Electroencephalography (EEG) and motor seizure durations and Hamilton 
Depression Rating Scale (HDRS) scores were used as primary measures of clinical 
outcomes. Two rounds of literature searches were conducted in the PubMed, Web of 
Science, and Google Scholar databases to identify randomized controlled trials and 
crossover trials that examined the effects of different intravenous sedatives and hypnotic 
agents on ECT. Two reviewers independently evaluated the internal validity and quality 
of studies, extracted data, and analyzed statistics. Utilizing all relevant data, standardized 
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mean differences (SMD) with 95% confidence intervals (CIs), and heterogeneity 
measures were calculated. Ten studies with 373 participants were included. 
Results: Thiopental only anesthesia was associated with longer EEG seizure duration 
when compared to propofol only treatment. The pooled effect size from studies with 
propofol anesthesia also suggests that this agent is associated with shorter seizure 
durations. If assessed individually with thiopental, the combination of ketamine and 
thiopental is correlated with increased motor as well as EEG seizure durations. When 
pooled; however, studies with patient groups assigned to anesthesia consisting of 
ketamine and another primary agent do not show significant differences either in EEG or 
motor seizure durations. Additionally, no difference exists in HDRS score reductions 
between propofol and methohexital. Of note; however, ketamine combined with either 
propofol or thiopental had significantly greater decreases in HDRS scores.  
Conclusion: Choice of anesthetic should be determined based on anticipated clinical 
outcome, adverse effect profile, reemergence, and patient preference. If long seizures are 
preferred, thiopental may be a reasonable option. However, if significantly larger 
decreases in depression score are preferred, then the combinations of ketamine and 
propofol or ketamine and thiopental appear to be the therapies of choice. Small sample 
sizes and insufficient clinical data limit the interpretations of these variables that 
determine therapeutic efficacy. Larger randomized control trials and crossover trials 
would provide greater insight into the optimal use of intravenous anesthetic agents with 
minimal adverse effects.  
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INTRODUCTION 
History of Electroconvulsive Therapy 
Invented in 1938, electroconvulsive therapy (ECT) is a biological procedure used 
for a range of neuropsychiatric illness such as major depressive disorder, manic disorder, 
and psychosis. ECT procedures are performed in multiple countries around the world; 
approximately 100,000 treatments occur in the United States annually1. 
 Historically, ECT represents a refinement of convulsive treatment developed by 
Ladislaus von Meduna, who induced epileptic seizures with camphor to treat 
schizophrenic patients. Utilizing existing neuropathologic studies of the time, Meduna, a 
Hungarian psychiatrist and pathologist, had recognized a contrast between the abundant 
glial cell growth in patients with epilepsy and the lack thereof in patients with 
schizophrenia2,3. Although Meduna postulated this particular biological antagonism 
between epilepsy and schizophrenia from the studies, his hypothesis was later rejected4.  
After inducing a brief series of convulsions with intramuscular injections of camphor in 
oil, Meduna enabled the full recovery of a schizophrenic patient who had suffered with a 
4-year catatonic stupor. Substituting camphor with pentylenetetrazol to increase 
predictability, Meduna proceeded to revolutionize this therapeutic modality for 
schizophrenia. While convulsive therapy’s successes facilitated its spread throughout 
Europe, its constraints, such as, exceedingly undesirable sensations and unpredictable 
timing, also became manifest. In order to ensure predictability, Italian scientists Cerletti 
and Bini developed the alternative method of using electric current for inducing seizures2.  
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After trying several possible positions for electrode placement in animals, 
Cerletti’s assistant, Bini discovered that the temples were safe sites for performing ECT. 
Once further animal testing demonstrated the safety of electrically induced seizures, 
Cerletti and Bini fine-tuned the stimulus parameters to enable therapeutic application in 
humans. They performed the first treatment of electroconvulsive therapy on a 39-year-old 
man, who was found meandering through a train station. Delusional, incoherent, and 
hallucinating, this patient was diagnosed with schizophrenia, after which he underwent 
the first ever ECT treatment on April 11, 1938. Although the efficacy of treating 
schizophrenia with induced convulsions had been previously demonstrated, the recovery 
of Cerletti’s patient after 11 ECT sessions had specifically established the safety of 
electrically induced convulsions2.   
Over the next few decades, ECT’s efficacy established its significance in treating 
severe psychiatric disorders. Multiple contributions to convulsive therapy including, “the 
introduction of general anesthesia, oxygenation, and muscle relaxing agents; and 
refinements in electrode placement, the seizure-inducing electrical waveform, and the 
informed consent process”4 have enhanced the tolerability, safety, and therapeutic 
efficacy of ECT. In the late 50s, with the serendipitous discovery of 
psychopharmacological treatment options, clinicians preferred treating patients with 
medications, which were easier to use, relatively inexpensive, and better accepted by 
patients. Political discourse and media depictions of ECT, illustrating the previous 
application of this modality without anesthesia, did little to promote the use of convulsive 
therapy in the 1950s and 1960s. As limitations of pharmacotherapy in the form of 
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treatment resistance and medication intolerance became evident, ECT continued to 
provide relief for these patients. After conducting a series of evaluations, professional 
organizations, psychiatric associations, and task forces affirmed the value of ECT in 
psychiatric medical practices around the world4. Since the late 80s, convulsive therapy 
has reemerged as an important tool for treating severe, treatment intolerant neuro-
psychiatric disorders5.  
 
Demographics and Current Practice 
ECT has been predominantly performed on patients with severe depression5,6, 
which is supported by demographic surveys from nations including the United States7, 
Spain8, Sweden9, Norway10, and New Zealand11. Among those treated with 
electroconvulsive therapy in US community hospitals, elderly patients, aged 65 or older, 
were 7 times more likely to undergo ECT treatment than patients between the ages of 18 
and 3412. This reflects that geriatric depression, which is often resistant to medication as 
well as psychotherapy, can be associated with higher mortality rates and become chronic 
in nature13. Greater sensitivity to adverse effects of psychotropic medications and 
comorbid medical diagnoses, which interfere with pharmacologic treatment,12 indicate 
the use of ECT as a treatment modality for the elderly13.  
Delivering electrical charge to the brain results in a generalized seizure14. The 
decision to treat an individual with ECT is based on two factors: diagnoses of MDD, 
mania, and psychosis with affective symptoms, and compelling clinical circumstance. 
Other reasons can be used to select ECT as the treatment of choice including clinical 
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urgency, risks associated with alternative treatments, resistance to medications, past 
medical history, or patient preference4. Current practice in the US is to conduct ECT in a 
hospital or clinic under the supervision of a psychiatrist and an anesthetist. ECT is 
administered after the patient is anesthetized and treated with a muscle relaxant14. 
 
Mechanisms of Therapeutic Action 
Anesthesia is integral to patient comfort. Since anesthetic agents act directly on 
the brain and neurotransmitters, they are important in the regulation of mood. Therefore, 
we will briefly summarize relevant hypotheses regarding ECT’s mechanisms of action to 
facilitate interpretations of the clinical effects mediated by different agents. ECT affects 
both the micro-environments and the macro environment of the brain by changing 
existing neuro-biological mechanisms, which can be further classified into 
neurophysiological, neuro-biochemical, and neuroplasticity theories.  
Neurophysiological: ECT delivers an electrical charge that propagates through the brain, 
resulting in the rapid depolarization of neurons as precipitated by changes in the 
intercellular electrical environments and ion concentrations. A convulsion ensues when a 
collection of depolarized neurons fire simultaneously. The generalized tonic-clonic 
seizure affects and involves critical brain structures such as the cortex, sub-cortex, 
thalamus, basal ganglia, and the limbic system.  
1. Cerebral Blood Flow: In the remitted state, patients with endogenous depression 
show reduced regional cerebral blood flow (rCBF) with greater decreases in the 
left hemisphere than in the right15. Takano et al. examined the changes in cerebral 
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blood flow (CBF) in patients immediately after acute ECT treatment. When 
compared to the pre-ECT state under anesthesia, the generalized seizure state is 
associated with increased global CBF. Whereas in missed (not generalized) 
seizures, global CBF quantities  were at intermediate levels between the previous 
two conditions. Figure 1 depicts global CBF levels in these three different 
conditions16. 
 
 
 
 
 
 
 
Figure 1. Global Cerebral Blood Flow. Global cerebral blood flow (gCBF) under 
anesthesia (pre-ECT), at missed and successful electroconvulsive therapy (missed ECT 
and ECT). **p <0.001 as compared to pre-ECT; +p < 0.1 between missed ECT and pre-
ECT, and pre-ECT and ECT, respectively.  Figure and caption obtained from Takano, 
201116.  
 
 
In contrast, Nobler et al. reported that depressed patients, who are not in the active 
seizure state, have global perfusion reductions as well as reduced rCBF in the 
frontal cortex a week following ECT completion17.  
2. Metabolism: Evidence points to persistent hypometabolic rates in the frontal gyri 
of individuals with unipolar or bipolar depression18. Henry et al. reported that 
patients showed significant decreases in global glucose metabolism, which were 
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correlated with decreases in HDRS, after treatment with bifrontotemporal ECT19. 
Nobler et al. noted widespread regions of reduced glucose metabolism following 
ECT as well. Consistent with Henry et al.’s study on reduced glucose metabolism 
after ECT, this finding posits the suppression of functional brain activity, 
particularly in the prefrontal cortex, as a putative mechanism of ECT’s therapeutic 
action. Nobler’s study not only records the decrease in frontal glucose metabolism 
after a course of ECT, but also significantly correlates these metabolic decreases 
with reductions in Hamilton depression scores20. While these findings regarding 
changes in the frontal lobes are consistent with the pathophysiology of depression, 
evidence suggesting reduced brain metabolism after ECT is not yet conclusive. 
For example, Mervaala et al. demonstrated regional metabolic increases in the 
right temporal and bilateral parietal cortices through increased uptake of ethyl 
cysteinate dimer (ECD) 1 week after ECT completion21.  
3. Electroencephalography: The EEG method detects the brain’s electrical activity, 
indicating changes in the functional integrity of the cerebral cortex. Signals 
measured during and after ECT may reflect the biological mechanism 
underpinning this treatment. A short-term increase in delta and theta power was 
visualized immediately after ECT; however, at a 2-month follow up, effective 
ECT forms produced an increase in delta power in prefrontal region22. Responders 
to ECT display higher amplitude, synchronous, and symmetrical ictal EEG 
changes, which were positively correlated with reductions in Hamilton 
Depression Rating Scale (HDRS) or Brief Psychiatric Rating Scale (BPRS) 
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scores23. Furthermore,  Nobler et al. reported that the postictal suppression after 
each ECT session is correlated with clinical improvement24.  
Neuro-biochemical: Administration of ECT dramatically, but transiently, increases 
neurotransmission, resulting in the release of various chemicals such as transcription 
factors, hormones, neurotropic factors and neurotransmitters25. These will be summarized 
below. 
1. Neurotropic: Mounting evidence suggests a role for neurotropic factors in the 
pathophysiology and management of psychiatric illnesses. Brain-derived 
neurotropic factor (BDNF) is a nerve growth factor that mediates growth, 
proliferation, survival, and renewal of neurons. Meta-analyses reveal lower levels 
of BDNF concentration in depressed patients than in healthy controls26; while 
increases in peripheral BDNF after ECT treatment have been reported, they do 
not necessarily correlate with improvements in symptoms25. Moreover, 
Kondratyev et al. reported that repeated exposure to electroconvulsive shock 
(ECS) significantly increases transcription of the gene encoding fibroblast growth 
factor-2 (FGF-2) in the frontal cortex as well as the nerve growth factor (NGF) in 
the limbic system, serving a neuroprotective function27. Vascular endothelial 
growth factor (VEGF), which stimulates endothelial proliferation, angiogenesis, 
and vaso-permeability, also deserves further investigation into its role in 
mediating ECT’s therapeutic effects28.  
2. Hormones: The hypothalamic-pituitary-adrenal (HPA) axis has been found to be 
dysfunctional in patients with depression as evidenced by enhanced cortisol 
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levels. Utilizing dexmethasone suppression testing, Hayes and Ettigi noted that, 
“…dexamethasone does not suppress cortisol levels in depressed patients as 
compared with normal subjects”29. Elevated cortisol levels have been implicated 
in the atrophy of neural structures, impairment of neurogenesis and gliogenesis, 
and thereby, inhibition of neuroplasticity. Patients with MDD who respond to 
ECT display a reduction of cortisol levels over time25. 
3. Neurotransmitters: Disordered monoaminergic transmission has been 
hypothesized as one of the pathophysiological mechanisms of major depression. 
Post mortem studies found decreased concentrations of noradrenaline, and 
increased alpha-2-adrenoreceptor binding. Rodent studies suggest that ECS might 
mediate its therapeutic effects by enhancing noradrenaline release.  This results in 
a decrease of alpha-2-adrenoreceptors in frontal-cortical areas projecting to the 
amygdala and hippocampus, structures respectively associated with the 
processing of emotions and memory.  
Several lines of evidence point to the involvement of dopaminergic 
mechanisms in the pathophysiology of mood disorders4. In Parkinson’s disease, 
repeated ECT treatment is correlated with a significant increase in cerebrospinal 
fluid (CSF) concentrations of the main metabolite of dopamine: homovanillic acid 
(HVA)4. In the rat brain, each administration of ECS resulted in the acute 
elevation of dopamine levels30 and increased D1 receptors31, reflecting a 
connection between ECS/ECT and dopaminergic effects. Reduced dopamine 
binding is visualized in structures including the substantia nigra, striatum, 
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thalamus, and anterior cingulate of MDD patients25. Thus, as Landau et al. 
suggest, increased dopaminergic transmission after ECT might play a therapeutic 
role in ameliorating symptoms of mood disorders and Parkinson’s disease32.   
An important neuromodulator in both physiological and pathological 
conditions, serotonin (5-HT), is hypothesized to play a significant role in 
depression25. Studies of tryptophan depletion, which is associated with decreased 
levels of serotonin, have consistently shown that recovered depressed patients 
experience symptomatic relapse in response to the release of serotonin precursors. 
Electrophysiological studies using rats, which are not depressed, report that 
repeated administration of ECS increases sensitivity of the post-synaptic-5HT1A 
receptor subtype in limbic structures33. While ECT’s effects on the serotonergic 
system are still debated, the role of serotonin in indicating the therapeutic efficacy 
of ECT in depressed patients is highly likely. 
Neuroplasticity- While psychiatric disorders have been associated with changes in the 
volumes of certain neural structures, studies also provide evidence of structural change in 
the brain as a result of ECT administration. ECT has been shown to excite 
synaptogenesis, neurogenesis, dendrogenesis, gliogenesis, and angiogenesis25. Abbott et 
al. found that the reduction in depressive symptoms correlated with increases in right 
hippocampal connectivity in patients after ECT. Additionally, the study reported an 
increase in the volumes of structures such as the right hippocampal cornu ammonis, 
dentate gyrus, and subiculum34. Joshi et al. provide evidence of increased structural 
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plasticity in the amygdala after ECT treatment with associated improvements in 
depressive symptoms. High-resolution motion-corrected images of brain structures                 
 reveal a change in amygdalar shape after electroconvulsive therapy. Figure 2 illustrates 
this change in patients after each ECT course35. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Longitudinal effect of ECT on local amygdalar shape. Top left panel shows 
significant local bilateral expansion in the dorsomedial amygdala as well as the left 
basolateral amygdala in patients across treatment time points. Top right panel shows 
significant expansions in the left basolateral amygdala in patients at T3 compared to T1. 
Figure and caption obtained from Joshi, 201635 
 
 The brain is organized into networks that are integral to the functions of the 
nervous system; these networks’ connectivity are reported to change among patients 
suffering with depression25. Leaver et al. found that ECT administered to depressed 
patients alters functional connectivity in certain regions of their brains such as the dorsal 
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anterior cingulate, to levels that are similar to those seen in control subjects. This 
normalization of functional connectivity with ECT was associated with clinical 
improvement of depressive symptoms36. While many mechanisms potentially explicate 
the physiological changes brought upon by the application of electroconvulsive therapy, 
certain conclusions are yet to be made. These suggestions for therapeutic action might not 
necessarily be mutually exclusive, but, in fact, multiple avenues of physiological and 
anatomical changes could combine to promote the changes enabled by ECT.   
 
Anesthesia 
 Since its inception in 1938, electroconvulsive therapy had been conducted without 
anesthesia for more than 20 years because modern medications and anesthetic techniques 
were yet to be introduced. When ECT was implemented without anesthesia and muscle 
relaxants, as many as 40% of patients incurred severe injuries including fractures, late 
onset seizures, teeth damage, and cardiovascular abnormalities. When modern anesthetic 
agents were developed, they were added to the ECT treatment protocol.  Some increased 
risks associated with modified ECT include, but are not limited to, intracranial 
hypertension, intracranial lesion, cerebral aneurysm, myocardial infarction, heart failure, 
etc. Necessitating standard American Society of Anesthesiologists monitors and 
medications, general anesthesia has become an integral component of ECT. 
Comprehensive monitoring for heart rate, blood pressure, ECG, capnography, and 
temperature are essential to the ECT setting as well as resources for the support and 
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resuscitation of unconscious patients. Table 1 lists common drugs utilized during the 
procedure37.  
Table 1. Drugs Commonly Utilized in ECT Procedures. 
 
Table 1 obtained from Bryson, 201737 
 
 
ECT treatment elicits a cardiovascular response that results from increased 
activation of both divisions of the autonomic nervous system. Parasympathetic activation 
in the tonic phase prompts bradycardia that lasts approximately 10-15 seconds38. 
Immediately following is the clonic phase, which is stimulated by a centrally mediated 
sympathetic response39, resulting in tachycardia and hypertension40. Direct sympathetic 
activity results in catecholamine release, which transiently increases systolic pressure by 
30-40%, and heart rate by 20% or more40. As such, the rate pressure product, which 
serves as a measure of myocardial oxygen consumption, increases by two- to four-fold41. 
Table 2 summarizes the physiologic responses to ECT40.  
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Table 2. ECT Induced Physiological Responses 
 
Common Physiologic Responses and Side Effects Associated with Electroconvulsive 
Therapy 
Variable Response 
Central Nervous System Increased blood flow velocity, intracranial pressure, and 
cerebral metabolism; dizziness, amnesia, confusion, 
agitation, and headaches 
Cardiovascular System 
Increased blood pressure, heart rate, and cardiac output; 
cardiac arrhythmias 
Musculoskeletal System 
Myoclonic-toxic contractions, bone fractures/dislocations, 
muscle and joint pain 
Miscellaneous Responses 
Increased salivation, nausea and vomiting, dental damage, 
and oral cavity lacerations 
 
Table 2 obtained from Ding, 200240 
 
 
The ideal anesthetic agent should achieve rapid induction, brief duration, and safe 
recovery without compromising seizure activity. As seizures serve as the therapeutic 
agents of an ECT course42,the duration of a seizure might be a potent indicator of 
therapeutic efficacy43. Depressed patients experience optimal clinical outcomes if their 
EEG seizure activity lasts anywhere between 25 and 50 seconds. Seizure activity lasting 
less that 15 seconds or greater than 120 seconds produces a less favorable response44. 
Associated anesthetic properties, influence on seizure duration, differential effects on 
hemodynamic parameters, and effects on clinical outcomes are some of the many factors 
that determine the choice of anesthetic agent45.  
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As many of the anesthetic agents inherently have anticonvulsant properties, they 
achieve a dose-dependent increase in seizure threshold. Defined as the minimal electrical 
intensity required to produce a generalized seizure of a specified minimal duration, 
seizure threshold is reported to vary among patients by more than 40-fold46. Henry et al. 
state that, “the initial dose of electricity should therefore be chosen to deliver a 
moderately supra-threshold stimulus” for therapeutic efficacy46. The authors also noted 
that stimulus intensities excessively exceeding seizure threshold are associated with 
memory difficulties and confusion4. Moreover, they suggest that a stimulus intensity 
250% above seizure threshold in right unilateral ECT can achieve a reasonable balance 
between treatment efficacy and adverse cognitive effects. As US ECT machines are 
capped at 576 mC, patients with higher seizure thresholds will not have a markedly 
supra-threshold treatment. Therefore, if ECT administration is standardized (all patients 
receive the same amount of electrical charge for treatment), patients with higher seizure 
thresholds might not receive efficacious treatment 44. Anesthetic choice, dose, and 
resultant effects on seizure threshold and systemic as well as cerebral hemodynamics 
must be carefully balanced to achieve a safe, effective ECT treatment that minimizes 
antagonistic effects and optimizes therapeutic outcome40.  
The first class of hypnotic agents utilized as anesthesia for ECT were the 
barbiturates. Methohexital is the most widely used and recommended oxybarbiturate for 
ECT in the United States today39. Although barbiturates are short acting agents that 
increase seizure threshold and decrease seizure duration, methohexital has the least effect 
on these factors45. Recommended dose for ECT induction ranges between 0.75 to 
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1.0mg/kg47. Onset of action occurs within a few seconds with effects lasting between two 
to eight minutes. Divided doses of methohexital have been suggested to minimize its 
anticonvulsant effects, extending seizure duration and improving outcomes48. Thiopental 
is an alternative barbiturate to methohexital for ECT anesthesia; however, it is associated 
with a shorter seizure duration. It is also associated with a higher frequency of 
arrhythmia, sinus bradycardia, premature atrial contractions, and premature ventricular 
contractions than methohexital49.  
Comparable to both methohexital50 and thiopental51, but with a shorter seizure 
duration, Sevoflurane has also been considered as an anesthetic option for ECT. A a 
volatile anesthetic, Sevoflurane, ensures rapid induction as well as emergence from 
anesthesia because it has a low blood-gas solubility with a partition coefficient of 0.6552. 
In some patients52, Sevoflurane has the effect of prolonging the Q-T interval53. 
Elongation of the QT interval can potentially trigger arrhythmias when sustained and is 
associated with ventricular tachycardia54. The use of Sevoflurane in patients who are 
taking adjunct antidepressant therapy is thus carefully monitored as antidepressant 
therapy can also prolong the interval53.  
 Propofol has also been explored as an anesthetic agent for ECT. It has similar 
pharmacokinetics to methohexital, and as such, ensures rapid onset of anesthesia. After 
injection of a single bolus dose, the agent distributes to the central nervous system in the 
form of lipid deposits; anesthesia lasts for 8 to 10 minutes before patients regain 
consciousness. Mainly metabolized in the liver, propofol is excreted in the urine as 
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inactive compounds. In addition to its anti-emetic properties, propofol can also have 
antipruritic, anxiolytic, bronchodilatory and anti-epileptic effects55. 
 Another commonly used anesthetic agent, ketamine, is a derivative of 
phencyclidine (PCP). Serving analgesic purposes in subanesthetic doses, this anesthetic is 
the most powerful N-Methyl-D-aspartate (NMDA)-receptor channel blocker available. 
Not only does ketamine act as PCP’s noncompetitive antagonist, but in interacting with a 
second membrane-associated site, ketamine also limits the frequency of channel opening. 
Although both the racemic mixture and S-enantiomer are marketed in some countries, 
only the racemic mixture is clinically available in the United States. After higher doses, 
such as an IV bolus dose of 0.9 to 1.1mg/kg, patients reach peak plasma levels and 
undergo a state of general anesthesia within 60 to 90 seconds. Apart from its role at the 
NMDA receptor, ketamine produces sympathomimetic action with increased 
catecholamine release and decreased reuptake37. Recent studies have found that ketamine 
possesses a rapid antidepressant effect in treatment-resistant depressed individuals56. 
Ketamine-induced NMDA receptor antagonism of gamma-aminobutyric acid 
(GABA)ergic interneurons activates glutamate release. Ensuing molecular and cellular 
responses, which stimulate processes such as synaptic potentiation and secretion of 
BDNF, may be important mediators of the antidepressant response to ketamine57. 
 Remifentanil is a potent opioid with analgesic properties58 that has also been 
proposed as an anesthetic option for ECT. Rather than serving as a choice for 
postoperative anesthesia, this agent is utilized for procedures with intense pain37. This 
analgesic has a rapid onset and offset of action with 3.65 minutes as the time needed for 
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50% reduction in effect site concentration. Opioids are currently under study for 
treatment resistant depression as they have limited effects on seizure threshold. 
Remifentanil is usually the agent of choice for patients who have higher seizure 
thresholds because it has low anticonvulsant tendencies37. 
 Opioid analgesics such as remifentanil can serve as intravenous adjuvants to 
benzodiazepine anesthetic agents. A benzodiazepine commonly used in clinical 
anesthesia is midazolam. In a double-blind randomized trial, Avramov et al. analyzed the 
sedative and analgesic effects of remifentanil alone versus that combined with different 
doses of midazolam (2mg, 4mg, or 8mg). The researchers reported that optimal sedation 
and analgesia were achieved when remifentanil was combined with 2mg midazolam59.  
Potentiating GABA’s neural inhibition, benzodiazepines are associated with effects such 
as sedation, reduced anxiety, and muscle relaxation. Not only is midazolam rapidly 
distributed, it has a relatively quick clearance with an elimination half life approximately 
between 1.7 and 2.6 hours60. As benzodiazepines are known for their anticonvulsant 
properties, which interfere with seizure induction by increasing seizure threshold37, they 
are often given along with opioids to minimize these effects. 
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METHODS  
Search Strategy 
As this systematic review aimed to examine the effects of different anesthetic 
agents on ECT’s therapeutic efficacy, literature searches for randomized controlled trials 
and crossover trials were conducted. Articles were obtained for inclusion using searches 
in the PubMed, Web of Science, and Google Scholar databases.  Search procedures were 
extensive with selective use of syntax and parameters to identify all articles for initial title 
and abstract screening. Terms and markers utilized in the research are described below.   
PubMed  
In all of the searches in this engine, the Search Builder included 
“Electroconvulsive Therapy [AND] Anesthetic Agent”. For the term, “Electroconvulsive 
Therapy”, the following markers were selected as Mesh terms to add onto the PubMed 
search builder: Adverse Effects, Analysis, Cerebrospinal Fluid, Classification, 
Complications, Drug Effects, Economics, Education, Epidemiology, Ethics, Etiology, 
History, Injuries, Instrumentation, Legislation and Jurisprudence, Manpower, 
Metabolism, Methods, Mortality, Nursing, Organization and Administration, 
Pharmacology, Physiology, Psychology, Standards, Statistics and Numerical Data, 
Supply and Distribution, Therapeutic Use, Therapy, Trends, Utilization and Veterinary. 
Through all the PubMed searches, these Mesh terms were consistently bridged under the 
overarching search words: Electroconvulsive Therapy.  
As PubMed failed to create a separate option to insert into the Search Builder for 
Methohexital, the same Mesh terms as those indicated for “Electroconvulsive Therapy” 
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were exclusively selected for this anesthetic agent. For all other induction drugs, the 
name generated a choice word that could be designated in the Search Builder. 
Web of Science & Google Scholar 
 To initially identify all related articles in the Web of Science, the search phrase 
included: “Electroconvulsive Therapy [AND] Anesthetic Agent”. 
 In the search engine, Google Scholar, two different phrases were employed to 
identify articles. While the first phrase stated “Electroconvulsive Therapy [AND] 
Anesthetic agent (name of agent)”, the second phrase was reversed in order to read, 
“Anesthetic agent (name of agent) [AND] Electroconvulsive Therapy”.  
 The web-based software tool, Covidence, was utilized for citation screening, full 
text reviews, and the extraction of studies in this review. Each reviewer independently 
sorted through all citations for applicability, inclusion criteria, and validity and finalized 
the data extraction. Two rounds of title and abstract screening were conducted to identify 
potentially relevant articles. Reviewers always discussed and reached an agreement 
before excluding studies. 
 
Study Selection 
Studies 
 Randomized controlled trials (RCTs) and crossover trials that fulfilled the 
following criteria were included: trials that assessed different agents during general 
anesthesia for ECT and their effects either on seizure duration and/or depression rating 
scales. The studies with the following anesthetic agents were included: Methohexital, 
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Propofol, Ketamine, Remifentanil, Sevoflurane, Midazolam and Thiopental. Trials had to 
be double-blind (i.e., clinicians and patients are unaware of treatment conditions) with 
either crossover or parallel-arm designs. Studies written in English and published 
between1975 and December 31st of 2017 were accepted. 
  Studies meeting the following criteria were excluded: 
1. Prospective and retrospective cohort studies, quasi-randomized studies, 
dissertations, theses, systematic reviews, commentary articles and abstract only 
documents. 
2. Open and single blind trials.  
3. Trials published prior to 1975 and after December 31st, 2017 and not written in 
English. 
Participants 
 Trials with 15 or more adult volunteers (≥ 18 years) with a primary diagnosis of 
Major Depressive Disorder according to Diagnostic and Statistical Manual of Mental 
Disorders –IV (DSM-IV) and equivalent diagnoses of the International Classification of 
Diseases (ICD)-10/ICD-9 were included. Studies with less than 15 adult volunteers who 
did not have a primary diagnosis of Major Depressive Disorder were excluded.  
Treatment Variables 
 Included RCTs and crossover trials compared different induction agents used 
prior to the administration of ECT, including: 
1. Intravenous sedative or hypnotic agent versus another intravenous sedative or 
hypnotic agent. 
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2. Intravenous sedative or hypnotic combined with a muscle relaxant versus another 
intravenous sedative or hypnotic combined with the same muscle relaxant. 
Outcome Measures 
Primary Outcomes 
1. ECT-induced seizure EEG and motor duration in seconds. 
2. Clinical remission of depressive symptoms, Hamilton Depression Rating 
Scale (HDRS) with a score of ≤ 7 for the 17-item version of ≤ 8 for the 21-
item version, ≤ 9 for the 25-item version61. 
 
Data Extraction and Analysis 
All data were assessed and recorded by two independent reviewers: one, a board 
certified psychiatrist and ECT practitioner (M.E.H) and the other, a graduate student 
(S.R.). The ten studies included in this review provide data before and after the 
application of the intervention or control measure. All papers included at least one control 
group and one treatment group. In five studies, the treatment and control group each 
consisted of one anesthetic agent. Five out of twelve studies combined two anesthetic 
agents into one interventional measure.  
Meta-analyses utilize the effect size statistic to compare quantitative results from 
different studies. While p values are calculated to analyze whether observed difference 
between treatment groups is likely due to chance, the effect size dictates the magnitude of 
the difference between groups. Standardized mean differences (SMD) and their 95% 
confidence intervals were calculated as effect size indices for the seizure duration and 
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HDRS scores. Standardized mean difference, or Cohen’s D, is defined by Kelley and 
Preacher as: 
 =
 −  
	

 
where  describes the mean of the jth group and 	
 is pooled estimate of the 
experimental and control groups62. An extent of difference between the means for two 
independent groups is thus operationalized by the standardized mean difference. Effect 
sizes of treatment arms affecting seizure duration in different studies were combined to 
create single pair-wise comparisons. Cohen’s d values for both EEG and motor seizure 
duration were calculated as the difference in means of the seizure duration divided by the 
pooled standard deviations between the two treatment groups.  
In order to evaluate changes in depression scores pre- and post- treatment, the 
effect size for the pretest-posttest-control (PPC) design is theoretically most applicable. 
This index allows for the estimation of treatment efficacy over a period of time when the 
control and treatment groups are dissimilar. This comparison of pre-post depression 
scores in the treatment group to those in a group without the intervention quantifies the 
magnitude of the interventional effect. The PPC design maximizes relevant quantifiable 
information in the trials by using pre-ECT depression scores, post-ECT depression 
scores, standard deviations, and number of participants in each control and treatment arm.  
While Becker provides an effect size measure called gppc1 for the PPC design, 
Scott Morris offers an unbiased estimate of the effect size defined as63:  
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This equation relays a better estimate of the population standard deviation as it 
assembles data from both treatment and control groups.  Although, Morris’s PPC design 
would have been most accurate, in order to obtain confidence intervals for the effect 
sizes, Kelley and Preacher’s Cohen’s d equation was utilized for depression scores. Using 
the change in depression score (before and after ECT) as the mean, the means and pooled 
standard deviations of the two treatment groups were used to find the Cohen’s d index. 
As suggested by Zhang and Han, the standard deviation of depression score change for 
each group was found using the following equation where B stands for baseline standard 
deviation64: 
 
 
All seizure duration times, scores from the HDRS, change in scores, and standard 
deviation values were entered into the Practical Meta-Analysis Effect Size Calculator 
established by Dr. David Wilson of George Mason University65. Resulting Cohen’s d 
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indices, variance, and confidence intervals were then utilized to find combined effect 
sizes for the meta analysis. 
 Data were analyzed using the random effects model, accounting for clinical 
heterogeneity, unpublished studies, and research possibly overlooked in the literature 
search. Meta analytic statistics using the standardized mean difference were obtained 
from the presentation, “Introduction to Meta-Analysis”, by Dr. Charles DiMaggio of 
Columbia University66. The weight of each study was calculated using the following 
equation:  
 
The following equation was utilized to find combined effect size: 
 
 
 
 
Confidence Intervals were found using these equations: 
 
 95% Confidence Intervals: 
 
 
Heterogeneity was measured using the Chi-squared and I-squared statistics. 
Values of p < 0.1 for the Chi-squared, and > 40% for the latter were indicative of 
heterogeneity. The Chi-squared statistic, Q, was calculated using the following equation: 
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The following equation was utilized to find I2: 
I2= 1- df/Q  
 
RESULTS 
Description of Studies 
 132 articles were screened, 10 trials published between 1994 and 2015 met study 
criteria and were included in this review. 373 participants with MDD were included in 
these trials. For the purposes of this thesis, studies were included if they assessed at least 
one of these outcome variables: impact on seizure duration and/or change in depression 
rating scale scores. Table III summarizes the included studies and their treatment groups
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Table III. Included Studies and Treatment Groups 
Study Study Author Year Trial Anesthetic Control Anesthetic n 
1 Auriacombe67 1995 Midazolam Methohexital 16 
2 Fear68 1994 Propofol Methohexital 20 
3 Geretsegger69 2007 Propofol Methohexital 50 
4 Butterfield70 2004 Propofol Thiopental 15 
5 Nasseri71 2009 Remifentanil + Thiopental Thiopental 48 
6 Abdallah72 2012 Ketamine + Thiopental Thiopental 14 
7 Loo73 2012 Ketamine + Thiopental Thiopental 46 
8 Rasmussen74 2014 Ketamine Methohexital 38 
9 Erdil75 2015 Ketamine + Sevoflurane Sevoflurane 84 
10 Alizadeh76 2015 Ketamine + Propofol Propofol 42 
 
Table IV summarizes the effects of anesthetic agents on motor seizure duration.  
 
 
 
 
 
Table IV. Effect of Anesthetic on Motor Seizure Duration 
Study Effect Size Statistic Effect Size p 
5 Cohen’s d -0.182 0.26 
6 Cohen’s  d 1.521 0.006 
10 Cohen’s  d 0.126 0.34 
8 Cohen’s  d 0.544 0.14 
9 Cohen’s  d -0.433 0.025 
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Table V presents the effect sizes of the anesthetic agents on EEG seizure duration. 
Table V. Effect of Anesthetic on EEG Seizure Duration 
Study Effect Size Statistic Effect Size p 
1 Cohen’s d -0.141 0.390 
2 & 3 Cohen’s d -0.492 0.020 
4 Cohen’s d -1.090 0.003 
6 & 7 Cohen’s d 0.165 0.260 
8 Cohen’s d 0.362 0.150 
9 Cohen’s d 0.122 0.290 
 
Table VI summarizes the impact of anesthetic agents on the Hamilton depression scale. 
 
 
 
Table VI. Effect of Anesthetic on Hamilton Depression Score 
Study Effect Size Statistic Effect Size p 
2 & 3 Cohen’s d 0.061 0.39 
6 & 10 Cohen’s d 0.650 0.010 
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Thiopental 
Nasseri et al. examined the effects of combining remifentanil with thiopental on 
seizure duration and hemodynamic changes. In the control group treated with thiopental 
only, EEG seizure duration was 49 (±17) seconds, while the intervention group with 
combined thiopental and remifentanil had a mean seizure duration of 46 (±16) seconds. A 
Cohen’s d value of -0.182 [-0.749, 0.385] (p=0.26) suggests that no difference exists in 
the seizure durations of the thiopental and the combined thiopental/remifentanil groups. 
Changes in depression score were not measured. 
Butterfield et al. used a crossover design to measure the effects of thiopental and 
propofol on EEG seizure duration. While propofol group yielded a mean seizure duration 
of 32.8 (±15.1) seconds, the thiopental group had an average duration of 47.2 (±11) 
seconds. A Cohen’s d value of -1.09 [-1.857, -0.323] tells us that thiopental was 
correlated with greater seizure duration, suggesting that the average patient receiving 
thiopental is likely to have a seizure duration that is 1.09 standard deviations above that 
of a patient receiving propofol (p=0.003). Butterfield et al. did not measure the effects of 
these anesthetic agents on alleviating depressive symptoms. 
Propofol 
 Two studies by Fear et al. and Geretsegger et al. analyzed the effects of propofol 
and methohexital on EEG seizure duration. The propofol treatment groups respectively 
produced seizure durations of 17.5 (±6.6) seconds and 44.3 (±18.9) seconds in the Fear 
and Geretsegger trials. Groups randomized to methohexital treatment had seizure 
durations of 25.5 (±9.3) seconds68 and 56.2 (±25.4) seconds69. An effect size of -0.492 [-
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0.968, -0.016] (p=0.02) suggests that methohexital is associated with longer EEG seizure 
duration68,69. 
The Butterfield, Fear, and Geretsegger studies, all of which compare propofol 
with another anesthetic agent, provide mean EEG seizure durations. When assessed 
together, the three studies indicate that when compared to propofol, the other anesthetic 
agents, thiopental and methohexital, are associated with greater seizure durations as the 
combined effect size is -0.78 [-1.18, -0.37], p=0.00001. Inter-study heterogeneity was 
significant for EEG seizure duration (I2=81.02%). 
 Only the Fear and Geretsegger studies utilized the HDRS score as an outcome 
variable. In the Fear et al. study, the propofol group had a mean depression score change 
of -13 (±4.526), while the methohexital group decreased by 13.2 (±4.378) points. 
Compared to the propofol group in the Geretsegger trial, which had a 16.7 (±5.021) point 
decrease in depression score, the methohexital group saw a 17.6 (±17.961) point 
decrease. When assessed together, the two trials indicate a lack difference between the 
efficacy of each anesthetic in decreasing depression scores (SMD = 0.06 [-0.41, 0.53], 
p=0.40). There was no significant heterogeneity for change in HDRS scores. 
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Table VII summarizes the combined effects of propofol versus another anesthetic agent on EEG duration. 
 
Table VII. Propofol versus Anesthetic, Combined Effect Size of EEG Duration 
 
Study 
Propofol 
n 
Mean 
(SD) 
Anesthetic 
n 
Mean 
(SD) 
Standardized Mean Difference (SMD) 
95% CI 
Weight 
SMD 
95% CI 
Butterfield 15 
32.80 
(15.10) 
15 
47.20 
(11.00) 
 
6.53% 
-1.09 
[-1.86, -0.32] 
Fear 9 
17.50 
(6.60) 
11 
25.50 
(9.30) 
4.43% 
-0.97 
[-1.91, -0.04] 
Geretsegger 25 
44.30 
(18.90) 
25 
56.20 
(25.40) 
12.08% 
-0.53 
[-1.10, 0.03] 
Total (95% 
CI) 
49  51  23.04% 
-0.78 
[-1.18, -0.37] 
 
Heterogeneity: Chi2 = 10.54, df = 2 (p=0.0051) I2= 81.02 
Z = -3.74 (p<0.00001) 
-5 -2.5 0 2.5 5
Favors Propofol         Favors 
Other
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Table VIII presents the combined effect size from comparisons between propofol and methohexital on decrease in 
HDRS scores. 
Table VIII. Propofol versus Methohexital, Combined Effect Size of HDRS Score Change 
Study 
Propofol 
n 
Mean 
(SD) 
Methohexital 
n 
Mean 
(SD) 
Standardized Mean Difference (SMD) 
95% CI 
SMD 
95% CI 
Fear 9 
-13.00 
(4.53) 
11 
-13.20 
(4.74) 
 
0.04 
[-0.84, 0.92] 
Geretsegger 25 
-16.70 
(5.02) 
25 
-17.60 
(17.96) 
0.07 
[-0.49, 0.63] 
Total (95% 
CI) 
34  36  
0.06 
[-0.41, 0.53] 
 
Heterogeneity: Chi2 = 0.023, df = 1 (p=0.88) I2= -42.48 
Z = 0.251 (p=0.40) 
 
-1 -0.5 0 0.5 1
Favors Propofol          Favors …
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Methohexital 
Although both the Fear and Geretsegger studies found methohexital to be 
associated with a longer EEG seizure duration than propofol, no difference was found 
between the durations of the methohexital group and the midazolam treatment group67. 
In the Rasmussen et al. study, the effects of methohexital and ketamine anesthesia 
on motor and EEG seizure duration were compared. The motor seizure duration was 
38.45 (±15.69) and 28.06 (±22.66) seconds for the ketamine and methohexital groups 
respectively. With an effect size of 0.544 [-0.107, 1.195], ketamine is associated with an 
increase in motor seizure duration, which tends toward significance (p=0.05). EEG 
seizure duration was 57.78 (±23.64) seconds in the ketamine group and 48.95 ± (25.24) 
seconds in the methohexital group. Unlike the trend in motor seizure duration, there is no 
significant difference in electrical seizure duration between the ketamine and 
methohexital groups (p=0.14). This study did not provide depression score statistics. 
Ketamine 
While ketamine alone was compared to methohexital in the Rasmussen study, this 
anesthetic agent was associated with increased motor seizure duration. In contrast, a few 
studies evaluated the effects of ketamine combined with another anesthetic agent versus 
those of the primary anesthetic agent alone. In the Abdallah et al. study, the addition of 
ketamine to thiopental resulted in a motor seizure duration of 41.4 (±9.53) seconds 
whereas the thiopental only group had a duration of 30.3 (±3.97) seconds. The combined 
anesthetic group was thus associated with a markedly prolonged motor seizure duration 
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(SMD = 1.521 [0.332, 2.711], p=0.006)72. The intervention group in the Alizadeh et al. 
study was treated with combined ketamine and propofol, while the control group was 
treated with propofol only. Motor seizure durations were 26.2 (±5.85) and 25.5 (±5.2) 
seconds for the combined ketamine/propofol and propofol groups, respectively. At a p 
value of 0.34, no significant difference existed between the motor seizure durations of the 
treatment and control groups. In contrast, the mixture of ketamine and Sevoflurane in the 
Erdil study resulted in a slight decrease in motor seizure duration. While the combined 
anesthetic group had a motor seizure duration of 23.7 (±5.3) seconds, the control group 
treated with Sevoflurane only had a duration of 26.2 (±6.2) seconds. A standardized mean 
difference of -0.433 [-0.865, 0.0002] (p=0.025)75, indicates that the Sevoflurane only 
group was associated with a  prolonged motor seizure duration. Significant heterogeneity 
was found for motor seizure duration.  
EEG seizure durations for the combined ketamine/thiopental group versus the 
thiopental only group in the Abdallah et al. study were respectively 57.3 (±14.29) 
seconds and 43.9 (±7.14) seconds. A significant effect size of 1.1864 [0.050, 2.322] 
(p=0.02) suggests that the combined anesthetic group was associated with increased 
seizure duration. In the Loo et al. trial, the treatment group also consisted of combined 
ketamine and thiopental anesthesia whereas the control group was treated with thiopental 
only. While the intervention group had an EEG seizure duration of 38 (±17.1) seconds, 
the control group had a mean seizure duration of 39 (±15.8) seconds. However, no 
significant difference in EEG seizure durations was found between the two groups. When 
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compared to the Sevoflurane only group with a seizure duration of 35.5 (±9.2) seconds, 
the ketamine/Sevoflurane combination group had a seizure duration that lasted 36.7 
(±10.5) seconds. No significant difference in EEG seizure durations existed between 
these two treatment groups either. When all these studies are considered together, the 
addition of ketamine to a primary agent does not change either motor seizure duration 
(SMD = -0.10 [-0.44, 0.24], p=0.28) or EEG seizure duration (SMD= 0.15 [-0.18, 0.48], 
p=0.18). Table IX summarizes and pools the effects of combination ketamine anesthesia 
on EEG seizure duration. 
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Table IX. Ketamine + Anesthetic versus Anesthetic, Combined Effect Size of EEG Seizure Duration 
Study 
Ketamine 
+ 
Anesthetic 
n 
Mean 
(SD) 
Anesthetic 
n 
Mean 
(SD) 
Standardized Mean Difference (SMD) 
95% CI 
Weight 
SMD 
95% CI 
Abdallah 7 
57.30 
(14.29) 
7 
43.90 
(7.14) 
 
2.98% 
1.19  
[0.05, 2.32] 
Loo 22 
38.00 
(17.10) 
24 
39.00 
(15.80) 
11.47% 
-0.06  
[-0.64,0.52] 
Erdil 41 
36.70 
(10. 50) 
43 
35.50 
(9.20) 
20.96% 
0.12  
[-0.31, 0.55] 
Total 
(95% 
CI) 
70  74  35.41% 
0.15 [-0.18, 
0.48] 
 
Heterogeneity: Chi2 = 4.02, df = 2 (p=0.13) I2= 50.25 
Z = 0.91 (p=0.18) 
-10 -5 0 5 10
Favors Ketamine              Favors 
Other
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Table X presents the combined effect size of supplementary ketamine anesthesia on motor seizure duration. 
 
 
Table X. Ketamine + Anesthetic versus Anesthetic, Combined Effect Size of Motor Seizure Duration 
Study 
Ketamine 
+ 
Anesthetic 
n 
Mean 
(SD) 
Anesthetic 
n 
Mean 
(SD) 
Standardized Mean Difference (SMD) 
95% CI 
Weight 
SMD 
 95% CI 
Abdallah 7 
41.40 
(9.53) 
7 
30.30 
(3.97) 
 
2.71% 
1.53 
[0.33, 2.71] 
Alizadeh 22 
26.20 
(5.85) 
20 
25.50 
(5.20) 
10.46% 
0.13 
[-0.48, 0.73] 
Erdil 41 
23.70 
(5.30) 
43 
26.20 
(6.20) 
20.49% 
-0.43 
[-0.87, 0.0002] 
Total 
(95% CI) 
70  70  33.66% 
-0.10 
[-0.44, 0.24] 
 
Heterogeneity: Chi2 = 7.44, df = 2 (p=0.02) I2= 73.12 
Z = -0.59 (p=0.28) 
 
-10 -5 0 5 10
Favors Ketamine           Favors Other
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 Only Abdallah et al. and Alizadeh et al. measured Hamilton Depression Rating 
Scales before and after each ECT session using two treatment groups: ketamine 
combined with an anesthetic versus anesthetic alone. The group randomly assigned to 
combination ketamine and thiopental treatment in the Abdallah trial, had a 12.4 (±4.68) 
point decrease in depression score, while the control group treated with thiopental only 
had a 17.9 (±4.20) point decrease. An effect size of 1.237 [0.094, 2.381] suggests that 
combined ketamine and thiopental yields a significantly greater decrease in depressive 
symptoms (p=0.02).  
 Combination treatment with ketamine and propofol in the Alizadeh et al. study 
results in a 19.3 (±4.738) point decrease in depression score compared to the propofol 
only group with a point decrease of 21.67 (±5.07). With a standardized mean difference 
of 0.4838 [-0.1305, 1.0982], p=0.02, combined ketamine and propofol treatment is also 
associated with a greater improvement from the depressive state. When collated, the data 
from the two trials suggest that mixing ketamine with an anesthetic agent is correlated 
with a significant decrease in the Hamilton depression score (SMD= 0.65 [0.11, 1.19], p= 
0.01). Significant heterogeneity was found for change in HDRS scores. Table XI presents 
the combined effect size of HDRS score change when ketamine is mixed with another 
anesthetic agent.  
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Table XI. Ketamine + Anesthetic versus Anesthetic, Combined Effect Size of HDRS Score Change 
Study 
Ketamine 
+ 
Anesthetic 
n 
Mean 
(SD) 
Anesthetic 
n 
Mean 
(SD) 
Standardized Mean Difference (SMD) 
95% CI 
Weight 
SMD 
 95% CI 
Abdallah 7 
-12.40 
(4.68) 
7 
-17.90 
(4.20) 
 
2.94% 
1.24  
[0.09, 2.38] 
Alizadeh 22 
-19.30 
(4.74) 
20 
-21.67 
(5.07) 
10.18% 
0.48  
[-0.13, 1.10] 
Total 
(95% CI) 
29  27  13.12% 
0.65  
[0.11, 1.19] 
 
Heterogeneity: Chi2 = 4.03, df = 1 (P=0.04) I2= 75.19 
Z = 2.36 (P=0.01) 
-10 -5 0 5 10
Favors Ketamine       Favors Other
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Figure 3. Funnel Plot. Effect sizes of EEG seizure duration measured in the included 
studies plotted against standard errors. Symmetrical plot indicates no bias. 
 According to the symmetry observed in the funnel plot above, there is no 
indication of publication bias. With a non-significant p value of 0.92, the Eger’s test 
confirms a lack of publication bias. 
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DISCUSSION 
Summary  
This systematic review assessed the impact of different anesthetic agents on the 
efficacy of ECT as measured by either seizure duration or change in the Hamilton 
Depression Rating Scale score.  10 trials with 373 participants were included. The 
following anesthetic medications or combinations were utilized in these trials: ketamine, 
propofol, methohexital, thiopental, midazolam, Sevoflurane, ketamine, ketamine and 
thiopental, ketamine and propofol, ketamine and Sevoflurane, and, lastly, remifentanil 
and thiopental.  Out of these 10 trials, data were pooled on studies with ketamine 
combined with another anesthetic (four trials), those comparing propofol with another 
anesthetic agent (three trials), and those comparing methohexital with another anesthetic 
(four trials).  According to this review, ketamine mixtures with propofol or thiopental 
appear to be the optimal choices for ECT because these combinations are associated with 
larger decreases in depression score than either propofol or thiopental alone. In order to 
effectively conduct risk-benefit analyses of using combination ketamine anesthesia for 
ECT, additional studies that assess side effect profiles of depressed patients treated with 
supplementary ketamine are warranted. 
 
Primary Outcomes  
A person’s seizure threshold is the minimal electrical dosage required to elicit a 
grand mal seizure. Sackeim et al. reported that higher seizure thresholds were associated 
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with shorter seizure durations44. Furthermore, Milstein and Small stated that patients with 
shorter seizure durations had less improvement in clinical outcomes than patients with 
longer seizure durations. Attributing it to a higher seizure threshold, the researchers claim 
that participants with shorter seizure durations presented relative treatment resistance77.  
Sackeim et al. hypothesized a couple of possible explanations to describe the relationship 
between threshold and treatment response.  
Given that US ECT machines are capped at 576 mC, one hypothesis suggests that 
if all patients receive the same amount of electrical charge, then those with lower 
thresholds receive a noticeably supra-threshold treatment. Conversely, for patients with 
higher seizure thresholds, the initial charge sufficient for those with lower seizure 
thresholds might not produce a seizure intensity that adequately exceeds their high 
threshold. As previously mentioned, the ideal stimulus dose should surpass seizure 
threshold by 250% to achieve a reasonable balance between treatment efficacy and 
unfavorable cognitive side effects4.  Therefore, according to standardized ECT 
administration, patients with high thresholds might not receive a therapeutic treatment44.  
It has also been hypothesized that patients with higher thresholds are more 
resistant to ECT because of a ceiling effect due to the rise of seizure threshold that occurs 
during treatment. Evidence of ECT producing a cumulative increase in seizure threshold, 
and, as such, a decrease in seizure duration, furthers this conjecture44. Higher stimulus 
intensities might not be adequately supra-threshold, but still contribute to adverse 
cognitive changes. As such, shorter seizure durations, which are tied to higher seizure 
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thresholds, are associated with less robust clinical outcomes than longer seizure 
durations.  
Compared to propofol, methohexital enables a longer seizure duration with an 
effect size measure of 0.491 [0.016,0.968]. However, far surpassing methohexital’s 
impact on EEG seizure duration with an effect size of 1.09 [0.323, 1.857], thiopental 
generates the greatest increase in seizure duration. With that large an effect size, there 
exists an approximately 78% chance that a random participant treated with thiopental 
anesthesia will have a higher EEG seizure duration than a participant treated with 
propofol78. When considering therapeutic efficacy of ECT as measured by seizure 
duration, thiopental is putatively the ideal agent to use.  
While adding ketamine to a primary anesthetic agent did not affect seizure 
duration, two trials were positive for alleviating depressive symptomatology. The 
treatment groups in the two trials, ketamine mixed with thiopental and ketamine added to 
propofol had a combined effect size of 0.65 [0.11, 1.19], p=0.01. This combined effect 
size suggests that the probability of a patient in the combined anesthetic group exhibiting 
a larger decrease in depression score than a person in the single anesthetic group is 
approximately 69%78. 
 
Limitations 
This systematic review is limited by the relatively small number of studies 
satisfying the inclusion criteria and the small sample sizes available within these studies. 
Larger randomized controlled trials can better elucidate the effects of anesthetic agents on 
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continuous outcomes such as seizure duration and depression score. Some studies 
provided limited data to assess clinical efficacy. Studies that utilized seizure duration as a 
proxy for therapeutic efficacy would have allowed for better interpretation of clinical 
outcome had they provided changes in patients’ depression scores with ECT treatment. If 
all studies had consistently measured seizure duration as well as depression scores, more 
information would have contributed to the clinical picture, and thereby, the systematic 
analysis of ECT efficacy.  
Another limitation was the number of ECT sessions in each study. As Sackeim et 
al. indicate, seizure duration reduces throughout a series of ECT treatments and 
eventually plateaus44. Thus, trials utilizing the final ECT’s seizure duration might miss 
clinically important changes that occur earlier in the course. To extend the utility of these 
studies, an analysis of the correlation between seizure duration and change in depression 
score might be informative. In this way, a putative relationship between seizure duration 
and therapeutic outcome can be examined in the context of ECT treatment for MDD.  
Since the depression scale score attempts to provide a direct measure of the 
clinical state of patients, this index serves as a more reliable indicator of ECT’s 
therapeutic efficacy than does seizure duration. Based on this analysis, ketamine 
combined with either propofol or thiopental appears to be the optimal choice for ECT as 
these mixtures are associated with larger decreases in depression score than anesthesia 
without supplementary ketamine. Future studies that assess the side effects of 
supplementary ketamine on depressed patients are necessary to perform risk-benefit 
analyses of using combination ketamine anesthesia in ECT treatment.  
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